Etsy's stock is falling after CEO warns of a decline in gross merchandise sales
Etsy Inc.'s (ETSY) stock declined 4% in extended trading Wednesday after the online-shopping site reported quarterly results that barely topped analyst revenue estimates and forecast a decline in gross merchandise sales. Etsy reported fiscal third-quarter net income of $87.9 million, or 64 cents a share, compared with a loss of $963.1 million, or $7.62 a share, in the same quarter a year ago. Revenue rose 7% to $636.3 million, from $594.5 million a year ago. "There's no doubt that this is an incredibly challenging environment for spending on consumer discretionary items," Etsy Chief Executive Josh Silverman said in a release. "It's therefore important to acknowledge that this volatile macro climate will make it challenging for us to grow this quarter." Analysts surveyed by FactSet had expected on average net earnings of 50 cents a share on revenue of $631.1 million. Shares of Etsy have slumped 49% this year, while the broader S&P 500 index has increased 10%.
-Jon Swartz
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
11-01-23 1702ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks